我要投票 汇仁HUIREN在乌鸡白凤丸行业中的票数:479
· 外 推 电 报 ·
2025-08-14 09:55:50 星期四

【汇仁HUIREN是哪个国家的品牌?】

汇仁HUIREN是什么牌子?「汇仁HUIREN」是 汇仁集团有限公司旗下著名品牌。该品牌发源于江西,由创始人陈冰郎在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力汇仁HUIREN品牌出海!将品牌入驻外推网,定制汇仁HUIREN品牌推广信息,可以显著提高汇仁HUIREN产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

汇仁集团创建于1992年,是一家按健康产业链拓展,产学研相结合,科工贸一体化,集成式发展的中国大型医药企业集团。总部位于历史名城江西南昌,现有员工4000余人,总占地面积约80万平方米,总资产超过20亿元。

汇仁集团秉承“仁者爱人”的核心理念,走出了一条独具特色的健康产业的发展之路,企业综合经济实力快速提升,2008年销售收入突破42亿元。跻身于江西省工业竞争力企业、中国工业行业排头兵企业、中国影响力民营企业等行列。“汇仁”商标被评为“驰名保护”和“中国医药行业影响力品牌”。集团总裁陈年代连续当选为十届、十一届全国人民代表大会代表。

汇仁集团坚持“致力振兴民族医药”和“科技是第一生产力”的发展观念,投巨资在中国药谷——上海张江高科技园区建设国家级研发中心,中心拥有向全国开放、国内规模最大的中试平台和一大批国际领先水平的仪器设施。先后引进了博士生导师、博士后、博士等二十多位高层次医药科研人才并建立了博士后工作站。几年来,完成了数十项药品研究开发任务,承担了十多项国家九五、十五科技攻关项目及多项国家级科研课题,与国家科技部生命科学发展中心、中国中医研究院、中国医药研究开发中心、中国医学科学院药用植物研究所、北京大学、中国药科大学、上海中医药大学等国内著名研究机构和院校保持良好的研究开发合作关系并取得了一大批研究成果。2005年,汇仁又在英国牛津科技园建立了欧洲研发中心。

强大的研发能力保证了汇仁产品的高品质和源源不断地推出疗效确切、价格低廉深受消费者欢迎的新产品。现在,汇仁已形成补益类、妇科儿科类、抗生素类、消化系统类、循环系统类中成药和化学药等10多个系列,9个剂型100多个规格的产品群。其中有10个产品拥有国家发明专利。

在全国,汇仁共有46个品种中药材GAP基地,总面积15000亩。按GAP要求建设的高标准、现代化的中药饮片厂可年产中药饮片15000吨。

2001年后,汇仁先后在江西、上海、郑州、深圳、哈尔滨等地收购和兴建了6家医药公司。位于江西南昌高新区的汇仁医药商业建有中部地区规模最大,配套设施最完备的医药仓储物流中心。短短的几年,汇仁医药商业已经雄踞江西医药商业首位,上海汇仁医药也已跻身上海医药商业前10名。

汇仁—一个伴随国家改革开放进程诞生发展起来的新兴企业。汇仁—一个融合中国人文传统与现代医药科技内涵的民族品牌。将继续秉承“仁者爱人”的核心理念,深耕中华大地,阔步走向世界。

英文翻译:Huiren group, founded in 1992, is a large pharmaceutical enterprise group in China, which is based on the development of health industry chain, the combination of production, learning and research, the integration of science, industry and trade, and the integrated development. Headquartered in Nanchang, Jiangxi, a historic city, with more than 4000 employees, the company covers an area of about 800000 square meters and total assets of more than 2 billion yuan. Huiren group adheres to the core concept of "benevolent people love others" and has embarked on a unique road to the development of health industry. The comprehensive economic strength of the enterprise has been improved rapidly. In 2008, its sales revenue exceeded 4.2 billion yuan. It has become one of the industrial competitive enterprises in Jiangxi Province, the leader of Chinese industrial industry, and the influential private enterprises in China. "Huiren" trademark is rated as "well-known protection" and "influential brand of Chinese pharmaceutical industry". Chen Shi, President of the group, was elected as the representative of the 10th and 11th National People's Congress. Huiren group adheres to the development concept of "striving to revitalize national medicine" and "science and technology is the first productivity". It has invested heavily in the construction of a national R & D center in Shanghai Zhangjiang High Tech Park, China Pharmaceutical valley. The center has the largest pilot test platform open to the whole country and a large number of international leading level instruments and facilities. More than 20 high-level medical research talents, including doctoral supervisor, postdoctoral and doctor, have been introduced and a postdoctoral workstation has been established. In recent years, it has completed dozens of drug research and development tasks, undertaken more than ten national science and technology research projects during the Ninth Five-Year Plan and the Tenth Five-Year Plan and many national scientific research projects, and cooperated with the life science development center of the Ministry of science and technology of the people's Republic of China, China Academy of traditional Chinese medicine, China Pharmaceutical Research and development center, Institute of medicinal plants of the Chinese Academy of Medical Sciences, Peking University, China Pharmaceutical University, Shanghai University of traditional Chinese medicine Many famous research institutions and colleges in China have maintained a good cooperative relationship in research and development and achieved a large number of research results. In 2005, Huiren established a European R & D center in Oxford Science Park, UK. The strong R & D ability ensures the high quality of Huiren products and continuously launch new products with precise curative effect and low price, which are popular with consumers. Now, Huiren has formed more than 10 series of products, including tonics, gynecology and pediatrics, antibiotics, digestive system, circulation system Chinese patent medicine and chemical medicine, and more than 100 specifications of 9 dosage forms. Among them, 10 products have national invention patents. In China, Huiren has 46 kinds of gap bases of traditional Chinese medicine with a total area of 15000 mu. According to gap requirements, the high standard and modern Chinese Herbal Pieces Factory can produce 15000 tons of Chinese herbal pieces per year. After 2001, Huiren successively acquired and built 6 pharmaceutical companies in Jiangxi, Shanghai, Zhengzhou, Shenzhen, Harbin and other places. Huiren pharmaceutical business, located in Nanchang high tech Zone, Jiangxi Province, has the largest medical storage and logistics center in the central region and the most complete supporting facilities. In just a few years, Huiren pharmaceutical business has ranked first in Jiangxi pharmaceutical business, and Shanghai Huiren pharmaceutical has also ranked in the top 10 of Shanghai Pharmaceutical business. Huiren - a new enterprise born and developed along with the process of national reform and opening up. Huiren is a national brand that integrates the Chinese cultural tradition and modern medical science and technology. We will continue to adhere to the core concept of "benevolent people love one another", deeply cultivate the land of China and stride towards the world.

本文链接: https://www.waitui.com/brand/ba570b826.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

沪指突破拉动公募赚钱效应,股基增量资金加速入市

公募机构的做多热情与赚钱效应,正通过指数突破行情得到直观印证。8月13日,沪指一举突破2024年10月8日创下的情绪高点3674.40点,并同步刷新2021年12月以来的指数新高。在指数突破的当日,公募基金产品的业绩表现呈现出显著的赚钱效应扩散特征——年内各类主题基金多点开花,高收益产品层出不穷,一举扭转了过去单一行业基金“独领风骚”的结构性行情特征。这一变化进一步推动股票型基金成为公募发行的核心品种,场外资金借道权益类产品加速涌入市场,既为资本市场注入增量流动性,又形成“行情—赚钱效应—资金流入”的正向循环,为股票市场的持续走强提供了有力支撑。(证券时报)

2小时前

公募基金费率改革不断提速,第二批浮动费率基金发行节奏显著快于预期

近日,记者从渠道获悉,中欧核心智选混合基金因募集规模突破20亿元提前结束发行,易方达价值回报混合同样宣布提前结束募集,第二批浮动费率基金发行节奏显著快于预期。近年来,公募基金费率改革不断提速。自证监会今年5月发布《推动公募基金高质量发展行动方案》以来,浮动费率机制被视为行业重点试点方向。此次中欧核心智选、易方达价值回报混合的提前结募,反映出该类产品正获得市场快速认可。(证券时报)

2小时前

印度Infosys公司将以1.53亿美元收购澳洲电信子公司75%的股份

印度IT服务公司印孚瑟斯(Infosys)周三表示,将以2.333亿澳元(约合1.53亿美元)收购澳大利亚电信集团(Telstra Group)旗下全资子公司Versent集团75%的股份。印孚瑟斯在一份声明中称,Versent集团为澳大利亚金融、能源、公用事业、政府和教育等行业的机构提供云服务。该交易预计将于 2026 财年下半年完成,但需获得澳大利亚外国投资审查委员会以及澳大利亚竞争与消费者委员会的批准。(新浪财经)

2小时前

以实际行动传递乐观情绪,公募频繁自购

公募自购热情不断升温,指数基金成为重要标的。近日,南方基金公告称,将以不少于2.3亿元的资金自购旗下多只权益类ETF。数据显示,今年以来公募自购权益类基金的净申购总额已经超过27亿元。业内人士认为,公募的自购行为,既能与基民利益绑定、为市场注入增量资金,也传递出对中国经济复苏动能的信心,以及对市场中长期趋势的乐观预判。(上证报)

2小时前

华泰证券:政策预期向好,把握银行结构性机会

36氪获悉,华泰证券指出,8月12日,财政部、央行、金融监管总局印发《个人消费贷款财政贴息政策实施方案》,年贴息比例为1%,中央财政、省级财政分别承担贴息资金的90%、10%,政府出资替代银行单边让利,有助于呵护息差,撬动信贷投放。7月31日国常会部署实施个人消费贷款贴息政策与服务业经营主体贷款贴息政策,8月以来工行、农行、建行、交行等多家银行积极响应个人消费贷款贴息政策与服务业经营主体贷款贴息政策。政策预期向好,把握银行结构性机会。

2小时前

本页详细列出关于汇仁HUIREN的品牌信息,含品牌所属公司介绍,汇仁HUIREN所处行业的品牌地位及优势。
咨询